Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2024 07:00 ET | Source: STALICLA

Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor

Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September 19, 2024 – STALICLA SA, a Swiss neuro precision...
July 09, 2024 07:00 ET | Source: STALICLA

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
June 27, 2024 07:10 ET | Source: STALICLA

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...
May 02, 2024 08:01 ET | Source: STALICLA

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder

Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the...
January 16, 2024 06:00 ET | Source: STALICLA

Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the...
March 27, 2023 07:25 ET | Source: STALICLA

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD The combination of STALICLA and...
March 08, 2023 06:00 ET | Source: STALICLA

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorderAgreement...
January 09, 2023 02:00 ET | Source: STALICLA

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

PRESS RELEASESTALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatmentThe transaction with Novartis reinforces STALICLA’s...